Illumina (NASDAQ:ILMN) Analyst Rating Consensus

Illumina (NASDAQ:ILMN) has received a short term rating of sell from experts at Zacks with a rank of 4. The stock has been rated an average of 2.38 by 16 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 11 Brokerage Firms have advised hold.

Other Equity analysts have also commented on the company shares. In the latest statement by the brokerage house, Citigroup maintains its outlook on Illumina (NASDAQ:ILMN). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm lowers the price target from $210 per share to $175 per share. The rating by the firm was issued on May 4, 2016.

Illumina (NASDAQ:ILMN) shares are expected to touch $157.46 in the short term. This short term price target has been shared by 13 analysts. However, the standard deviation of short term price estimate has been valued at 28.2. The target price could hit $235 on the higher end and $125 on the lower end.

Illumina (NASDAQ:ILMN) witnessed a decline in the market cap on Tuesday as its shares dropped 0.75% or 1.05 points. After the session commenced at $140.31, the stock reached the higher end at $140.87 while it hit a low of $137.53. With the volume soaring to 1,008,205 shares, the last trade was called at $139.05. The company has a 52-week high of $242.37. The company has a market cap of $20,468 million and there are 147,200,000 shares in outstanding. The 52-week low of the share price is $127.1.

Shares of Illumina Inc. appreciated by 0.93% during the last five trading days but lost 1.04% on a 4-week basis. Illumina Inc. has dropped 11.07% during the last 3-month period . Year-to-Date the stock performance stands at -27.56%.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.